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SUMMARY
Howbreast cancers are able to disseminate andmetastasize is poorly understood. Using a hyperplasia trans-
plant system, we show that tumor dissemination and metastasis occur in discrete steps during tumor pro-
gression. Bioinformatic analysis revealed that loss of the transcription factor GATA-3 marked progression
from adenoma to early carcinoma and onset of tumor dissemination. Restoration of GATA-3 in late carcino-
mas induced tumor differentiation and suppressed tumor dissemination. Targeted deletion of GATA-3 in
early tumors led to apoptosis of differentiated cells, indicating that its loss is not sufficient for malignant con-
version. Rather, malignant progression occurred with an expanding GATA-3-negative tumor cell population.
These data indicate that GATA-3 regulates tumor differentiation and suppresses tumor dissemination in
breast cancer.INTRODUCTION
Mortality from breast cancer arises primarily from metastatic col-
onization of distant organs, but currently there is no curative
treatment for metastatic disease. The term ‘‘malignant progres-
sion’’ describes the process by which a benign tumor acquires
the ability to colonize distant organs to form metastases (Cham-
bers et al., 2002; Gupta and Massague, 2006; Weigelt et al.,
2005). Although malignant progression has been the subject of
scrutiny for decades, it remains poorly understood owing to the
complexity of the process and the difficulty of modeling it in the
laboratory. Tumor cells must successfully accomplish a number
of cellular processes to form metastases, including evasion of
immune responses and programmed cell death, invasion of the
host stroma, escape through vasculature and/or lymphatics,
and survival and growth in distant sites (Chambers et al., 2002).
Much of the work on metastasis is based on experimental sys-tems, such as orthotopic xenografts or tail vein injections, that
do not model all of the steps necessary for metastasis formation.
As a result, many fundamental aspects of malignant progression
remain poorly understood. For instance, at what time point during
tumor progression does dissemination to distant sites begin? Of
all the steps in metastasis formation, which is rate limiting?
One clue to a cellular basis of metastasis formation comes
from pathologic analysis of epithelial cancers, which has estab-
lished a strong correlation between the differentiation status of
a primary tumor and its metastatic potential (Bloom and Richard-
son, 1957; Contesso et al., 1987; Liu et al., 2007). Well-differen-
tiated breast tumors, such as fibroadenomas, tend to have a low
capacity for metastasis formation, while poorly differentiated
breast tumors, such as invasive ductal carcinomas, have
a high capacity for metastasis. Although this correlation holds
true for the large majority of solid tumors, there is currently little
molecular understanding for why this is so. For instance, doesSIGNIFICANCE
During malignant progression, a primary tumor acquires the ability to form metastases. The differentiation status of a pri-
mary tumor strongly predicts its metastatic potential. The cell fate regulator GATA-3 is a strong and independent predictor
of clinical outcome in human luminal breast cancer. Here we show that loss of GATA-3 marks the expansion of a stem cell-
like population during the early stages of malignant progression in a mouse model of luminal breast cancer. Restoration of
GATA-3 in undifferentiated mammary adenocarcinomas was sufficient to induce tumor differentiation and inhibit tumor dis-
semination. These data suggest that GATA-3 causally links the differentiation status of a tumor with its malignant potential
during breast cancer progression and raise the possibility of its use in differentiation therapy.
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GATA-3 Suppresses Breast Cancer Disseminationthe loss of differentiation causally lead to metastasis formation,
or are these events simply correlative?
To identify molecular markers of malignant progression, a se-
ries of 11 independent microarray profiling studies (1009 patients
in total) compared the gene expression signatures of well-differ-
entiated, low-metastatic breast tumors and poorly differentiated,
high-metastatic breast tumors (Bertucci et al., 2000; Farmer
et al., 2005; Gruvberger et al., 2001; Hoch et al., 1999; Mehra
et al., 2005; Perou et al., 2000; Sorlie et al., 2003; Sotiriou et al.,
2003; van ’t Veer et al., 2002; Wang et al., 2005; West et al.,
2001). The transcription factor GATA-3 emerged as a strong
predictor of tumor grade, estrogen receptor status, and progno-
sis in breast cancer. Meta-analysis of four microarray data sets
found that low GATA-3 expression was a strong and indepen-
dent predictor of metastasis formation and poor clinical outcome
(Mehra et al., 2005). Further, log-rank analysis of human micro-
array data and patient survival identified GATA-3 as the second
best predictor of breast cancer survival among 8024 genes
(Jenssen et al., 2002). Immunohistochemical and tissue microar-
ray studies confirmed these findings (Hoch et al., 1999; Jac-
quemier et al., 2005; Mehra et al., 2005). Taken together, these
studies indicate that breast tumors with high GATA-3 expression
tend to be well differentiated with low metastatic potential, while
tumors with low GATA-3 expression tend to be poorly differenti-
ated with high metastatic potential.
Recently, we and others have shown that GATA-3 regulates lu-
minal cell differentiation in the mammary gland (Asselin-Labat
et al., 2007; Kouros-Mehr et al., 2006). GATA-3 is necessary
both for the differentiation of mammary stem cells into mature
luminal cells and for the maintenance of the differentiated luminal
epithelium in the adult mammary gland. In this report, we explore
the role of GATA-3 in tumor progression using the mouse mam-
mary tumor virus LTR-driven polyoma middle T antigen (MMTV-
PyMT) transgenic mouse, which is an accurate and reliable model
of human luminal breast cancer (Guy et al., 1992; Herschkowitz
et al., 2007; Lin et al., 2003). Using a hyperplasia transplant
system that enables the stereotyped dissection of the steps in
metastasis formation, we show that GATA-3 is a critical regulator
of tumor differentiation and that its loss underlies the onset of
tumor dissemination during tumor progression.
RESULTS
A Transplant Model to Study Metastasis Formation
in Breast Cancer
The MMTV-PyMT mouse develops spontaneous mammary tu-
mors that progress from hyperplasias to poorly differentiated ad-
enocarcinomas (Guy et al., 1992; Lin et al., 2003). However,
these mice develop hundreds of distinct tumor foci in their mam-
mary glands, making it difficult to follow the metastatic potential
of tumor foci over time. To examine the progression of single
tumor foci over time, we generated bitransgenic MMTV-PyMT;
b-actin-enhanced green fluorescent protein (GFP) mice in the
FVB/n strain and microdissected intact GFP-positive hyperpla-
sias (0.7–1.0 mm) from 3-week-old females (Figure 1A). Intact
hyperplasias were then transplanted into the gland-free mam-
mary fat pads of wild-type, syngeneic recipient mice and allowed
to develop for 5, 8, 12, 15, or 18 weeks. The outgrowths exhibited
a stereotyped tumor progression (Figures 1B–1D). By 5 weeks,
142 Cancer Cell 13, 141–152, February 2008 ª2008 Elsevier Inc.the outgrowths progressed to well-differentiated adenomas
that were encapsulated in basement membranes and expressed
milk proteins, such as b-casein. By 8 weeks, there was a stereo-
typed progression to early carcinoma, characterized by the loss
of basement membrane, epithelial architecture, and milk protein
production. By 18 weeks, the outgrowths progressed to poorly
differentiated adenocarcinomas. The median time to palpable
tumor in the transplant model was 63 days (n = 24).
Tumor Dissemination and Metastasis Are Distinct
Events during Malignant Progression
To characterize malignant progression in the transplant model,
we determined the onset of tumor cell dissemination during neo-
plastic progression. We detected single GFP+ tumor cells in the
lung, liver, spleen, brain, and kidneys of host mice beginning at
8 weeks posttransplantation, suggesting that tumor dissemina-
tion began precisely during the transition from adenoma to early
carcinoma (Figure 1E, Figure S1 for negative control). Tomato-
lectin staining revealed that the disseminated cells in the lungs
were entrapped in the lung vasculature (n = 20, Figure 1F), sug-
gesting that the cells had reached the lungs by a hematogenous
route. The number of disseminated cells in the lungs of tumor-
bearing mice increased steadily from 8 to 18 weeks posttrans-
plant (Figures 1H and 1I). By 18 weeks posttransplant, several
thousand disseminated cells were present in the lungs of
tumor-bearing mice.
We then performed a pulse-chase experiment to track the met-
astatic capability of these disseminated cells. Tumor transplants
were allowed to grow for a varying pulse period (5, 8, 12, 15, and
18 weeks) and were then removed by mastectomy. Mice were
sacrificed after a constant chase period (8 weeks postmastec-
tomy) to allow the single cells to grow into metastases, and their
organs were analyzed for metastasis. Interestingly, metastases
were detected after the 8-week chase period from the 15- and
18-week outgrowths and not from the 5-, 8-, or 12-week out-
growths (Figures 1G, 1J, and 1K). Thus, although tumor dissem-
ination began at 8 weeks posttransplant, the capacity to form
metastases was acquired later, at 15 weeks posttransplant. We
did not detect any single disseminated tumor cells in any tu-
mor-bearing mouse after the 8-week chase period (n = 208 sec-
tions from 26 mice). Moreover, we only detected an average of
one to two metastases per mouse in the lungs of 18-week tumor
mice after the 8-week chase period, suggesting that the over-
whelming majority of disseminated cells had been destroyed
(Figure 1K). This suggests that the rate-limiting step in metastasis
formation is the extravasation and growth of disseminated cells
that arrive in distant sites. A subset of mice in which the tumors
recurred locally after mastectomy died within the 8-week chase
period due to heavy metastatic burden in lungs (n = 4). Metasta-
ses were not detected in other organs, suggesting that there
is a tissue-specific tropism for metastasis formation in this
model. Taken together, these data indicate that tumor dissemi-
nation and metastasis occur at distinct times during tumor
progression in the MMTV-PyMT model.
Loss of GATA-3Marks Loss of Differentiation and Tumor
Progression in Mammary Adenocarcinomas
We used a bioinformatics strategy to identify molecular markers
of malignant progression in this model. The RNA expression
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GATA-3 Suppresses Breast Cancer DisseminationFigure 1. Dissemination and Metastasis Occur at Distinct Progres-
sion Steps in a Breast Cancer Hyperplasia Transplant Model
(A) Focal hyperplasia isolated from a 3-week-old MMTV-PyMT; b-actin GFP
mouse.
(B–D) Representative (B) GFP whole mount, (C) H&E staining, and (D) b-casein
(green)/DAPI(blue) immunofluorescence of 5-, 8-, and 18-week tumor out-
growths. White arrowhead denotes early carcinoma adjacent to adenoma (yel-
low arrow) in an 8-week outgrowth.
(E) Brightfield (upper) and GFP (lower) whole mount of the lungs of an 18-week
tumor-bearing mouse.
(F) Immunofluorescence of GFP (green), DAPI counterstain (blue), and tomato
lectin (vasculature, red) of disseminated tumor cells in the lung of a tumor-
bearing mouse (18-week outgrowth).profiles of the adenomas (5-week outgrowths) and late carcino-
mas (18-week outgrowths) were compared by microarray analy-
sis. Analysis of the data revealed that the most differentially
expressed genes between adenomas and carcinomas were
luminal differentiation genes. Of the six most differentially ex-
pressed genes between adenomas and carcinomas, five were
associated with luminal differentiation (Table 1). Milk protein
genes (Whey Acidic Protein, a-lactalbumin, and several caseins)
and estrogen receptors were markedly downregulated in carci-
nomas as compared to adenomas (Figure 2A). As in human
breast cancer, tumor progression in this model strongly coin-
cided with a loss of luminal cell differentiation. Importantly, the
luminal cell fate regulator GATA-3 was downregulated in carci-
nomas and was the only member of the GATA family to be differ-
entially expressed. Immunofluorescence staining showed that
nearly all tumor cells in 5-week adenomas were positive for
GATA-3 and that 8-week early carcinomas displayed partial
loss of GATA-3, but the tumor cells in 18-week late carcinomas
were GATA-3 negative (Figure 2B). Interestingly, the small frac-
tion of 18-week tumor outgrowths that failed to disseminate
were GATA-3 positive (Figures 1H and 2D). Disseminated
tumor cells (n = 10) and metastases (n = 6) in the lungs of tumor-
bearing mice were consistently GATA-3 negative (Figures 2E and
2F). Thus, the loss of GATA-3 marked the loss of tumor differen-
tiation and the onset of tumor dissemination, suggesting that
GATA-3 loss is a bona fide marker of malignant progression in
this model.
We further analyzed GATA-3 expression in a series of human
breast cancer cell lines and mouse models of breast cancer
(Figure 2C). Using a gene expression database of the NCI-60
cell lines (Ross et al., 2000), we observed that the human breast
cancer cell lines MCF-7 and T-47D, which have features of differ-
entiated mammary cells and have low metastatic potential,
displayed high GATA-3 expression. In contrast, the poorly differ-
entiated, highly metastatic cell lines MDA-N, BT-549, HS-578T,
and MDA-MD-231 all demonstrated significant (>60-fold) down-
regulation of GATA-3 expression relative to the differentiated
cell lines. Loss of GATA-3 also coincided with tumor progression
in three additional mouse models of breast cancer, MMTV-Neu,
MMTV-Wnt1, and C3(1)/Tag, but the rate and extent of GATA-3
loss varied between the models (Figures 2G–2I). In the MMTV-
Neu model, which is a luminal mammary adenocarcinoma
model similar to the MMTV-PyMT model, early adenomas ex-
pressed GATA-3, while carcinomas lost GATA-3 expression
(Figure 2G). In C3(1)/Tag mice, adenomas displayed partial
GATA-3 loss, while carcinomas were GATA-3 negative. The
(G) Brightfield (upper) and GFP (lower) whole mount of a lung with metastasis
(arrowhead). Shown is the lung of a mouse sacrificed 8 weeks after removal of
an 18-week tumor outgrowth.
(H and I) Tumor dissemination rate (percent mice with dissemination) (H), and
frequency (total projected number of disseminated cells) (I) in the lungs of tu-
mor-bearing mice at 5 (n = 5), 8 (n = 8), 12 (n = 7), 15 (n = 4), and 18 weeks (n = 7)
posttransplant.
(J and K) Lung metastasis rate (percent mice with lung metastases) (J) and fre-
quency (total number of lung metastases) (K) of tumor outgrowths. Mice with
tumor outgrowths of 5 (n = 5), 8 (n = 5), 12 (n = 5), 15 (n = 6), and 18 weeks
(n = 5) underwent mastectomy and were sacrificed 8 weeks later. Data are rep-
resented as mean ± SEM. (I and K). Scale bars correspond to 1 mm (A, B, E,
and G), 25 mm (C), and 5 mm (D and F).
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rectly (Goetz et al., 2001), in agreement with our observation
(Figure 2H). In MMTV-Wnt1 mice, which develop multilineage
tumors, adenomas were GATA-3 positive and the loss of
GATA-3 was first detected in carcinomas. However, approxi-
mately one-third of the tumor cells in carcinomas were GATA-3
positive (Figure 2I). Since MMTV-Wnt1 neoplasias contain clonal
populations of mature luminal and myoepithelial progenitor cells,
the Wnt1-driven progenitor cells likely continue to produce
differentiated progeny even late in tumor progression (Li et al.,
2003).
GATA-3 Is Sufficient to Induce Tumor Differentiation
and Repress Dissemination in Breast Cancer
Given the essential role of GATA-3 in maintaining mammary lu-
minal cell differentiation (Kouros-Mehr et al., 2006), we assessed
its ability to regulate tumor differentiation and metastasis in
mammary adenocarcinomas using a retroviral delivery strategy.
Primary cultures of nonfluorescent MMTV-PyMT carcinomas
were infected with empty vector retrovirus or retrovirus contain-
ing mouse GATA-3 cloned into an IRES-GFP cassette and trans-
planted into the cleared mammary fat pads of wild-type mice, by
published methods (Welm et al., 2005). After 6 weeks of growth,
the tumor cells infected with empty vector formed poorly differ-
entiated adenocarcinomas with no ductal architecture (Fig-
ure 3A). In contrast, the GATA-3-infected tumors expressed milk
proteins (b-casein) and basement membrane components
(perlecan) and formed clusters of ducts indicating that the tumor
cells were functionally differentiated (Figure 3A). Microarray
analysis of GATA-3-infected and control-infected tumor out-
growths confirmed that GATA-3 induced the expression of
Table 1. Most Differentially Expressed Genes during Tumor
Progression
Name Symbol n1a n2 n3 Average
Casein ab Csna 4.3 3.6 4.0 3.9
Fatty acid bp4 Fabp4 3.9 2.8 3.8 3.5
Casein gb Csng 2.8 4.0 3.6 3.5
Carbonic anhydrase 6b Car6 2.3 2.3 3.1 2.6
Whey acidic proteinb Wap 2.8 2.0 2.6 2.4
Carbonic anhydrase 3b Car3 2.6 2.0 2.2 2.3
Lipoprotein lipase Lpl 2.4 2.0 2.0 2.1
Zinc finger prot 503 Zfp503 2.1 2.2 1.5 1.9
Riken 3021401L19 2.4 1.9 1.4 1.9
Adipsin And 2.3 1.2 2.2 1.9
Thyroid SPOT14 hom Thrsp 2.1 1.5 1.9 1.8
Lactalbumin ab Lalba 1.0 2.3 1.9 1.7
Sterol carrier prot 2 Scp2 2.2 1.7 1.3 1.7
Acyl-CoA synth L4 Acsl4 1.9 1.6 1.6 1.7
CDC-like kinase 1 Clk1 1.6 1.8 1.7 1.7
Catenin D 1b Ctnnd1 2.3 1.1 1.6 1.7
Tumor diff exp 1 Tde1 1.6 1.5 1.8 1.6
a Values represent M = log2(Cy5/Cy3) ratio: Cy3, labeled 18-week carci-
noma total RNA; Cy5, labeled 5-week adenoma total RNA.
b Indicates genes associated with luminal differentiation.
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proteins such as caseins, a-lactalbumin, and Whey Acidic Pro-
tein (WAP) (Figure 3B). FOXA1, a transcription factor and down-
stream effector of GATA-3 (Kouros-Mehr et al., 2006), was also
upregulated in GATA-3-infected tumor outgrowths relative to
controls (M = 0.6, 1.5-fold change; data not shown).
We then determined whether GATA-3 restoration affected the
metastatic capability of the resulting tumors. GATA-3-infected
tumors had abundant cystic structures filled with secretory ma-
terial and were two-fold larger in tumor size relative to controls
(n = 5 per group; p < 0.01, Figure 3C). Despite being larger than
controls, the GATA-3-infected tumors exhibited a 27-fold reduc-
tion in tumor dissemination in the lungs of tumor-bearing mice
(p < 0.01, Figure 3D). This difference was not due to a difference
in GFP expression, as theGATA-3 and control tumor outgrowths
expressed similar levels of GFP (data not shown). Interestingly,
the few disseminated cells found in the lungs of GATA-3-trans-
duced tumor-bearing mice were GATA-3 negative (n = 10)
(Figure 3F). Moreover, immunostaining of the GATA-3-infected
primary tumors revealed regions that were GATA-3 negative
(Figure 3E), suggesting that there is a negative selection pressure
on GATA-3 during breast cancer progression. These data indi-
cate that GATA-3 is sufficient to differentiate mammary ductal
adenocarcinomas and that the absence of GATA-3 is necessary
for tumor dissemination in breast cancer.
The Premature Loss of GATA-3 in Early Tumors
Is Not Tolerated
We considered the silencing of the GATA-3 locus in differenti-
ated tumor cells as a potential mechanism for the loss of
GATA-3 during malignant progression. We therefore character-
ized the status of theGATA-3 locus in MMTV-PyMT late carcino-
mas. Sequencing of theGATA-3 promoter and full-length gene in
18-week carcinomas failed to identify somatic mutations (data
not shown). However, bisulfite sequencing of the same regions
identified a number of methylated cytosine residues in the
GATA-3 promoter and first exon (Figure S2). The highest con-
centration of methylated cytosines occurred in the first exon of
GATA-3, consistent with an earlier study of human breast tumors
(Yan et al., 2000).
To test the silencing hypothesis further, we assessed the con-
sequences of GATA-3 loss in differentiated neoplastic cells
through inducible, targeted deletion of the GATA-3 locus in early
MMTV-PyMT adenomas. The floxedGATA-3construct (GATA-3fl)
was designed such that Cre-mediated recombination leads to
the induction of GFP expression (Pai et al., 2003). We targeted
expression to differentiated luminal mammary epithelial cells
with the doxycycline-inducible WAP-rtTA-Cre (Kouros-Mehr
et al., 2006; Utomo et al., 1999). First, we tested our deletion
strategy by administering a 7-day course of doxycycline to triple
transgenic MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/+ mice with
mixed early and late carcinomas and analyzing GFP expression
to assess recombination (Figure S3). As expected, GATA-3-pos-
itive (differentiated) areas of the tumor were also GFP positive,
indicating recombination of the floxed GATA-3 locus. Undiffer-
entiated areas of the tumor lacked GATA-3 and remained GFP
negative, indicating that recombination only occurred in well-
differentiated tumor cells.
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Progression in Breast Cancer
(A) Clustered image map of microarray data com-
paring Cy5-labeled (red) 5-week tumor outgrowth
and Cy3-labeled (green) 18-week outgrowth (n = 3
microarrays). Color intensity represents M = log2
(Cy5 fluorescence/Cy3 fluorescence). ER, estro-
gen receptor; CA, carbonic anhydrase; WAP,
whey acidic protein.
(B) Immunofluorescence staining for GFP (green)
and GATA-3 (red) and DAPI counterstain (blue) in
5-, 8-, and 18-week tumor outgrowths (n = 3 per
condition). White arrow denotes early carcinoma
in 8-week tumor outgrowth adjacent to an ade-
noma (yellow arrow).
(C) Relative GATA-3 expression levels in nine
breast cancer cell lines from a microarray data
set (Ross et al., 2000). Data are represented as
log2 ratios of GATA-3 expression relative to control
genes from a reference RNA in the pool of 60 cell
lines.
(D) Immunofluorescence staining for GATA-3 (red)
and DAPI (blue) counterstain in a representative
18-week tumor outgrowth in which tumor dissem-
ination to lungs was undetectable by histologic
analysis.
(E) Immunofluorescence staining of a representa-
tive disseminated cell in the lung of an 8-week tu-
mor-bearing mouse (same color scheme as [B]).
(F) Immunofluorescence staining for GATA-3 (red)
and DAPI (blue) in a representative lung metastasis
from a MMTV-PyMT mouse.
(G–I) H&E staining and immunofluorescence for
GATA-3 and DAPI in the MMTV-Wnt, MMTV-
Neu, and C3(1)/Tag mouse models of breast can-
cer. Representative adenomas and carcinomas
are shown from 9-month-old MMTV-Neu mice in
the FVB/n strain (n = 12 mammary glands from
three mice), 6-month-old C3(1)/Tag mice in the
FVB/n strain (n = 11 mammary glands from three
mice), and 4.5-month-old MMTV-Wnt1 mice in
the FVB/n strain (n = 8 mammary glands from three
mice) that were analyzed for GATA-3 expression.
Scale bars correspond to 25 mm (B, D, and F–I) and
10 mm (E).We then assessed the acute and long-term consequences of
GATA-3 deletion in mice with early tumors. After a 2-week
course of doxycycline, the tumors of 10-week-old control
MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/+ mice appeared well
differentiated with cystic elements and high GATA-3 and milk
protein (b-casein) expression (Figure 4A). In contrast, MMTV-
PyMT; WAP-rtTA-Cre; GATA-3fl/fl mice displayed premature
loss of differentiated tumor cells, characterized by loss of milk
protein expression and widespread tumor cell detachment
from basement membrane. These cells underwent apoptotic
cell death in the ductal lumen as indicated by cleaved cas-
pase-3 immunostaining. The resulting tumors contained elon-
gated ducts that were devoid of cells or secretory material. After
an additional 6 weeks of doxycycline (8 weeks total), control
mice displayed a heavy tumor burden with progression to inva-
sive carcinoma and concomitant loss of GATA-3 (Figures 4B
and 4C). In contrast, MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/fllittermates had significantly smaller tumors, presumably due to
widespread cell loss. Interestingly, the resulting tumors con-
tained a population of cells that were GATA-3 positive, GFP
negative, and cytokeratin 18 positive, suggesting that these lu-
minal cells had avoided DNA recombination and remained
GATA-3 positive. Taken together, these data suggest that the
premature loss of GATA-3 in well-differentiated adenomas is
not sufficient to promote malignant progression. Thus, the
mechanism by which GATA-3 is lost during tumor progression
may not involve the silencing of the GATA-3 locus in differenti-
ated cells.
Tumor Progression Involves the Expansion of a GATA-3-
Negative Cell Population with Cell Surface Markers
of Mammary Stem-like Cells
An alternative hypothesis to account for the loss of GATA-3 dur-
ing tumor progression is the expansion of a tumor population
Cancer Cell 13, 141–152, February 2008 ª2008 Elsevier Inc. 145
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mor Differentiation and Dissemination in
Breast Cancer
(A) H&E staining and immunocytochemistry for
b-casein, perlecan (heparan sulfate proteoglycan),
GFP, GATA-3, and nuclei (DAPI) in vector control
and GATA-3 retrovirally transduced tumor out-
growths. Primary cultures of adenocarcinomas
from 14-week-old MMTV-PyMT mice (nonfluores-
cent) were transduced with retrovirus, trans-
planted into the mammary fat pads of wild-type
mice, and grown for 6 weeks.
(B) Clustered image map of microarray data com-
paring Cy5-labeled (red) GATA-3 retrovirally in-
fected tumor outgrowths and Cy3-labeled (green)
control-infected tumor outgrowths (n = 3 microar-
rays). Color intensity represents M = log2 (Cy5
fluorescence/Cy3 fluorescence). ER, estrogen re-
ceptor; CA, carbonic anhydrase.
(C and D) Volume of tumor outgrowths and fre-
quency of tumor dissemination in lungs of vector
control (n = 5)- and GATA-3 (n = 5)-infected tumor
outgrowths.
(E and F) Immunofluorescence for GATA-3 (red),
GFP (green), and DAPI (blue) in GATA-3-infected
tumors (E) and in a disseminated tumor cell (F) in
lung arising from a GATA-3-infected tumor.
Error bars indicate SEM; *p < 0.01 (Student’s t
test). Scale bars correspond to 25 mm (A and E)
and 10 mm (F).that is GATA-3 negative. A recent study found that mammary ep-
ithelial stem cells are GATA-3 negative (Asselin-Labat et al.,
2007). This population can be isolated through sorting of mam-
mary epithelial cells for the cell-surface markers CD24, CD29
(b1 integrin), and CD61 (b3 integrin). The CD24+CD29loCD61+
subpopulation of mammary epithelial cells is enriched for luminal
progenitor cells, while the CD24+CD29+CD61+ subpopulation,
characterized by serial passage and functional assays, is en-
riched for mammary stem cells (Asselin-Labat et al., 2007;
Shackleton et al., 2006; Stingl et al., 2006). Accordingly, we char-
acterized primary epithelial cells from early and late MMTV-
PyMT tumors and normal mammary glands using these markers.
We found that the populations of CD24+CD29+ and CD29+CD61+
cells progressively increased in carcinomas (93% and 76%, re-
spectively), compared to early tumors/adenomas (55% and
33%, respectively) and normal mammary epithelial cells (45%
and 16%, respectively) (p < 0.001, Figures 5A and 5B). Further
immunohistochemical staining showed that the CD29+CD61+
tumor cells in early and late tumors were GATA-3 negative
(Figure 6). Thus, early tumors and carcinomas contained a pro-
gressively enriched subpopulation of CD24+CD29+CD61+ cells.
Similar results were found in MMTV-PyMT tumors from the
C57BL/6 (Figure 5A) and FVB/n strains (Figure S4).
We isolated the populations enriched in putative stem-like
cells (CD24+CD29+CD61+) and differentiated cells (CD24+
146 Cancer Cell 13, 141–152, February 2008 ª2008 Elsevier Inc.CD29CD61) from early tumors and normal mammary glands
by FACS and assessed cellular motility in a transwell migration
assay (Figure 7A). Interestingly, after 72 hr of incubation, the
CD24+CD29+CD61+ cell population from normal mammary
glands and early tumors displayed a significantly enhanced
migratory potential compared to CD24+CD29CD61 cells.
Compared to the CD24+CD29CD61 population, the CD24+
CD29+CD61+ cell fractions from normal mammary glands and
early tumors exhibited greatly enhanced migration potential
(Figure 7B).
If the tumor cells of late carcinomas have features of stem-like
cells, we predicted that they should be bipotential, capable of
giving rise to both luminal and myoepithelial cells. Further exam-
ination of the late carcinomas retrovirally infected with GATA-3
(Figure 3A) revealed that these carcinoma cells had given rise
to multiple cell lineages (Figure 7C). The reverted tumors con-
tained GATA-3-positive luminal cells as well as GATA-3-nega-
tive, smooth muscle actin-positive myoepithelial cells. Taken to-
gether, these results indicate that MMTV-PyMT early tumors and
carcinoma cells contain a progressively enriched subpopulation
of highly motile cells that shares some properties with mammary
stem cells, which were defined as GATA-3 negative (Asselin-
Labat et al., 2007). Our data suggest that expansion of this tumor
subpopulation underlies the emergence of the GATA-3-negative
state during tumor progression.
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GATA-3 Suppresses Breast Cancer DisseminationFigure 4. Deletion of GATA-3 Is Not Tolerated in Differentiated Tumors
(A and B) H&E staining and immunofluorescence for GATA-3, GFP as a marker of Cre-mediated deletion (CreGFP), b-casein as a differentiation marker, Keratin 18
as a luminal epithelial marker, a-smooth muscle actin (SMA) as a marker of myoepithelial cells, cleaved caspase-3 as a marker of apoptosis, and DAPI counter-
stain in tumors of 10-week-old MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/+ and MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/fl mice treated with doxycycline for 2 weeks
(n = 8 tumors) (A) or 8 weeks (n = 16 tumors) (B). Black arrows indicate caspase-3-positive cells in the ductal lumen. Insets are higher-magnification views. Scale
bars correspond to 25 mm.
(C) Mean tumor volume of tumors at 8 weeks of doxycycline for MMTV-PyMT; WAP-rtTA-Cre; GATA-3fl/+ (GATA-3fl/+) and MMTV-PyMT; WAP-rtTA-Cre;
GATA-3fl/fl (GATA-3fl/fl). Error bars indicate SEM (n = 16 tumors); *p < 0.01 (Student’s t test).DISCUSSION
GATA-3 Causally Links Tumor Differentiation
and Tumor Dissemination
In the present study, we developed a modified model of the
MMTV-PyMT mouse that facilitates the study of breast cancer
progression, including the events that lead to tumor dissemina-
tion and metastasis. We found that malignant conversion begins
with the loss of tumor differentiation and the onset of tumor dis-
semination that coincides with the transition from a GATA-3-
positive adenoma state to a GATA-3-negative early carcinoma
state, as shown in the model in Figure 7D. Disseminated tumor
cells in distant sites were GATA-3 negative, suggesting that
the GATA-3-negative state is required for tumor dissemination
to commence. Restoring GATA-3 was sufficient to induce tumor
differentiation and suppress tumor dissemination. These data
suggest that GATA-3 normally controls the differentiation of lu-
minal tumor cells and that selection against GATA-3 expression
is a critical event in the early steps of malignant progression. The
importance of tumor differentiation (tumor grade) in predicting
malignant potential of human breast tumors has been appreci-
ated for decades, and our data suggest that GATA-3 is a molec-
ular link between these processes.In agreement with our observations, GATA-3 is a strong and
independent predictor of clinical outcome in breast cancer,
with its low expression indicating a poor prognosis (Bertucci
et al., 2000; Farmer et al., 2005; Gruvberger et al., 2001; Hoch
et al., 1999; Mehra et al., 2005; Perou et al., 2000; Sorlie et al.,
2003; Sotiriou et al., 2003; van ’t Veer et al., 2002; Wang et al.,
2005; West et al., 2001). Low GATA-3 expression is strongly as-
sociated with higher histologic grade, positive lymph nodes,
larger tumor size, estrogen receptor (ER) and progesterone re-
ceptor (PR) loss, and HER2 overexpression. Indeed, the prog-
nostic utility of GATA-3 exceeds that of conventional variables
such as ER status (Jenssen et al., 2002). These studies correla-
tively link low GATA-3 expression with poor tumor differentiation
and metastatic formation in human breast tumors. Our study
suggests that GATA-3, in fact, plays a causal role in tumor differ-
entiation and metastasis formation in breast cancer.
Metastatic Capability of Disseminated Tumor Cells
in Breast Cancer
Our transplant model allowed us to follow the progression of a sin-
gle tumor focus growing orthotopically in an immune-competent
mouse. We have shown that tumor dissemination and metastasis
formation occur in discrete steps during tumor progression. The
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disseminated cells can successfully give rise to a metastasis.
Since most disseminated cells appear to be trapped in the vascu-
lature, the rate-limiting step in metastasis formation is likely to in-
volve extravasation, survival, and proliferation of disseminated
cells in distant sites. In keeping with these data, microarray anal-
ysis of human breast cancers indicates that GATA-3 expression
levels in metastases are consistently lower than their corre-
sponding primary tumors (Weigelt et al., 2003). Thus, although
progression to a GATA-3-negative state underlies the onset of
tumor dissemination, further events are likely to be necessary
for successful formation of metastases from disseminated cells.
In the MMTV-PyMT transgenic mouse model, these events
likely do not arise from random mutagenesis of key target genes
because the model has a very low rate of somatic mutagenesis
(Jakubczak et al., 1996) and genomic instability (Hodgson et al.,
2005). One possibility is that the development of a premetastatic
niche in distant sites is necessary for the successful formation of
a metastasis (Kaplan et al., 2005). Alternatively, it is possible that
only a rare cell within the primary tumor, such as a tumor stem
cell, is capable of successfully completing all of the various steps
of metastasis (Pardal et al., 2003). A similar kinetic analysis of
metastasis in other mouse models of breast cancer, such as the
MMTV-Wnt1 and MMTV-Neu mice, may further shed light on
the nature of metastasis formation in breast cancer.
Expansion of GATA-3-Negative Tumor Cells
during Breast Cancer Progression
We found that the targeted loss of GATA-3 in early tumors is not
sufficient to induce malignant progression. This suggests that
Figure 5. A Stem Cell-like Population Is Enriched in Late Carcino-
mas in MMTV-PyMT Tumors
(A) Representative CD24/CD29 and CD61/CD29 contour plots of C57BL/6
primary cells isolated from wild-type mammary glands, 11-week early, non-
palpable MMTV-PyMT tumor and a 5-month MMTV-PyMT tumor measuring
13 3 20 3 8 mm. Values in each quadrant indicate the percentage of cells in
each condition (n = 10,000 events).
(B) Percentage of CD61+, CD24+CD29+ double-positive, and CD24+CD61+
double-positive cells in samples described in (A). A total of three to four sam-
ples were analyzed per condition. Error bars indicate SEM; *p < 0.001 (analysis
of variance).
148 Cancer Cell 13, 141–152, February 2008 ª2008 Elsevier Inc.the silencing of the GATA-3 locus in differentiated tumor cells
is not the primary molecular mechanism that leads to the
GATA-3-negative state in breast cancer. An alternative mecha-
nism for the development of GATA-3-negative tumor cells is
Figure 6. Immunohistochemical Staining of CD29, CD61, andGATA-3
in MMTV-PyMT Tumors
(A) Immunofluorescence for CD29 (green), CD61 (red), and DAPI (blue) on
frozen sections of 7-week-old (early) and 14-week-old (late) MMTV-PyMT
tumors. Early1 and Early2 refer to two distinct areas within the same tumor.
(B) Immunofluorescence for GATA-3 (red) and DAPI (blue) on serial sections of
the tumors in (A). Adjacent, acetone-fixed frozen sections were thawed,
processed with microwave antigen retrieval, and labeled with GATA-3 as
described (Kouros-Mehr et al., 2006). Scale bar, 25 mm.
Cancer Cell
GATA-3 Suppresses Breast Cancer DisseminationFigure 7. Stem Cell-like Populations from MMTV-PyMT Tumors Show Increased Motility and Ability to Differentiate into Luminal and
Myoepithelial Cells
(A and B) Analysis of motility among distinct cell populations purified from wild-type mammary glands and early MMTV-PyMT tumors. (A) Transwell migration
assays performed on CD24+CD29+CD61+ (stem cell-like) and CD24+CD29CD61 (differentiated cell) subpopulations purified from normal mammary glands
(C57BL/6, n = 2) and adenomatous MMTV-PyMT tumors (C57BL/6, n = 2). Cells were isolated with a FACSAria cell sorter, and 1.5 3 105 cells were used per
condition. After 72 hr, the membranes containing migratory cells were stained (A) and the fraction of the membranes containing stained cells were determined
using Adobe Photoshop (B). Error bars indicate range.
(C)GATA-3-transduced tumor outgrowths haveboth luminal and myoepithelial cells.Primary culturesofadenocarcinomas from14-week-old MMTV-PyMT mice (non-
fluorescent) were transduced with retroviruses encoding vector alone (Vector) or GATA-3 (GATA-3), transplanted into the mammary fat pads of wild-type mice, grown
for 6 weeks, and then stained for GATA-3 (red) and a-smooth muscle actin (SMA, green) by immunofluorescence, and nuclear staining with DAPI. Scale bar, 25 mm.
(D) Model showing how GATA-3 expression and differentiated luminal epithelial markers may be lost through expansion of a GATA-3-negative stem cell-like cell pop-
ulation during MMTV-PyMT tumor progression. The biomarkers estrogen receptor (ER) and whey acidic protein (WAP) were described by Lin et al. (2003).the expansion of tumor population that has not activated the
GATA-3 locus. We found that adenomas and carcinoma cells
were progressively enriched for cell-surface markers of mam-
mary stem-like cells, which were shown previously to beGATA-3 negative (Asselin-Labat et al., 2007). Early adenoma-
tous tumors contained an increased population of these
GATA-3-negative stem-like cells, suggesting that a small popu-
lation of these cells reside in early tumors and that selective
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cinomas in the MMTV-PyMT model, such cells comprised nearly
the entire tumor mass and are capable of differentiating into both
luminal and myoepithelial cells. These putative tumor stem-like
cells exhibited significantly enhanced motility compared to the
differentiated cell population, suggesting that tumor invasion
and dissemination may be carried out by this expanding tumor
cell subpopulation. Interestingly, the restoration of GATA-3 in
late carcinomas led to the differentiation of both luminal and
myoepithelial lineages, suggesting that carcinoma cells are indeed
bipotential. A major question that arises is what elements in the
tumor microenvironment foster the selection and dominance of
this GATA-3-negative cell population. Further work will be nec-
essary both to characterize this cell population and to delineate
its role during malignant progression and the mechanisms that
underlie their expansion during tumor progression.
Differentiation Therapy in Breast Cancer
GATA-3 is critical for cell survival, terminal cell differentiation, or
cell-type specific function in many nontransformed tissues such
as CD4 T cells, NK cells, skin, and developing mammary gland
(Ho and Pai, 2007), and our data indicate that it functions as a dif-
ferentiation agent in carcinomas as well. Differentiation therapy
describes the enforced differentiation of primary tumors with
therapeutic compounds. In acute promyelocytic leukemia,
a t(15;17) translocation leads to deficiencies in retinoic acid re-
ceptor signaling, a block in myeloid differentiation, and neoplas-
tic transformation (Weis et al., 1994). High-dose retinoic acid
therapy and chemotherapy are sufficient to restore tumor differ-
entiation and achieve remission in patients (Tallman et al., 1997).
Our work suggests that compounds that activateGATA-3may
be sufficient to differentiate mammary ductal adenocarcinomas.
Alternatively, compounds that prevent the loss of GATA-3 may
prevent breast cancer progression in patients. Though it is tech-
nically feasible to screen drug libraries to identify such com-
pounds, a more rational approach to drug discovery is to identify
upstream regulators of GATA-3 signaling. In development, the
specification of GATA expression is mediated by secreted fac-
tors, notably the Wnt genes (Davidson et al., 2002). In the devel-
oping mammary gland, specific Wnt members are expressed at
sites of luminal specification (Kouros-Mehr and Werb, 2006). A
molecular understanding of GATA-3-mediated luminal cell spec-
ification could reveal further insights into a differentiation therapy
of breast cancer.
EXPERIMENTAL PROCEDURES
Mice
MMTV-PyMT (FVB/n), MMTV-Neu (FVB/n), MMTV-Wnt (FVB/n), and b-actin-
GFP (FVB/n) mice were from Jackson Labs. MMTV-PyMT (C57BL/6) mice
were provided by Dr. Kasper Almholt. WAP-rtTA-Cre (C57BL/6) and C3(1)/
Tag mice (FVB/n) were obtained from the NCI mouse models consortium.
GATA-3fl/+ mice (on the C57BL/6 background) were generated as described
(Pai et al., 2003). Although tumor progression is significantly delayed in
MMTV-PyMT mice crossed onto the C57BL/6 strain relative to the FVB/n
strain, the tumors are indistinguishable when compared at relative stages.
Tumor Transplantation
All animal experiments were performed with protocols approved by the UCSF
IACUC. MMTV-PyMT (Guy et al., 1992) (FVB/n) mice were bred with b-actin-
GFP reporter mice (FVB/n) to allow visualization of the mammary epithelium.
150 Cancer Cell 13, 141–152, February 2008 ª2008 Elsevier Inc.Focal hyperplasias (0.7–1 mm) were microdissected from 3-week-old female
MMTV-PyMT; b-actin-GFP mice using a fluorescence dissecting microscope.
The intact hyperplasias were transplanted into the cleared mammary fat pads
of 3-week-old female FVB/n recipients. Tissues were fixed by cardiac perfu-
sion fixation of mice followed by overnight fixation in 4% paraformaldehyde
(PFA) at 4C. Biotinylated tomato lectin (100 ml, 1 mg/ml, Vector Laboratories)
was injected into the tail vein prior to cardiac fixation for visualization of vascu-
lature.
Analysis of Tumor Dissemination and Metastasis
The PFA-fixed lungs of tumor-bearing mice were OCT embedded, and frozen
sections were prepared such that all five lobes were analyzed for tumor dis-
semination and metastasis. Lung sections (25 mm separated by 200 mm inter-
vals) were analyzed for GFP expression using a Leica DMR microscope with
a broad-pass filter that allowed the distinction between autofluorescence (or-
ange/red color) and GFP (green). Only GFP-positive cells with nuclei (DAPI)
were included in the analysis. The total number of disseminated cells per
lung was calculated by averaging the number of GFP+ cells in eight 25 mm sec-
tions (5% of total lung volume) and extrapolating to the full thickness of the
lung. Metastases were detected by whole-lung analysis with a fluorescence-
dissecting microscope and then by the same histologic analysis.
Microarray Analysis
RNA was extracted with Trizol Reagent (Tel-Test), reverse transcribed in the
presence of amino-allyl-dUTP, and coupled to CyScribe dyes (Amersham),
as described (Barczak et al., 2003). Cy5- and Cy3-labeled samples were hy-
bridized onto 70-mer oligonucleotide spotted microarrays with 38,784 fea-
tures (MEEBO set, UCSF Functional Genomics Core). Lowess print-tip nor-
malization of microarray data and analysis were performed using the Acuity
software package.
Immunofluorescence
Immunofluorescence was performed on PFA-fixed, paraffin-embedded tumor
sections with antibodies and protocols as previously described (Kouros-Mehr
et al., 2006). Additionally, immunostaining with anti-cleaved-caspase-3 (Cell
Signaling) was performed at a dilution of 1:250. CD29 (ABD Serotec, clone
HM beta 1-1) and CD61 (BD, clone 2C9.G2) immunostaining were performed
on acetone-fixed frozen tumor sections at dilutions of 1:50 and 1:100, respec-
tively, and on adjacent acetone-fixed frozen sections with anti-GATA-3 (Santa
Cruz Biotechnology, clone HG3-31) at 1:20 after sodium citrate antigen
retrieval.
Conditional Deletion of GATA-3
MMTV-PyMT (C57BL/6) mice were bred with GATA-3fl/+ mice, and the result-
ing offspring were bred with WAP-rtTA-Cre; GATA-3fl/+mice. Genotyping and
doxycycline administration were performed as previously described (Kouros-
Mehr et al., 2006).
Retroviral Transduction of Tumors
Full length GATA-3 (Zhang et al., 1999) was cloned into the pMIG vector for ret-
roviral production (Van Parijs et al., 1999). Primary cultures of adenocarci-
nomas from nontransplanted 14-week-old MMTV-PyMT mice (FVB/n) were in-
fected with retrovirus and cultured for an additional 3 days (Welm et al., 2005).
GFP-positive cells were isolated using a FACSAria Cell sorter, and 500,000
cells were transplanted into the cleared mammary fat pads of 3-week-old fe-
male FVB recipients. Mice were harvested 6 weeks later. Tumor size was de-
termined by measuring with calipers and calculated as length 3 width 3
height/2.
Methylation Analysis
Genomic DNA was isolated from an 18-week tumor outgrowth, and bisulfite
treatment was carried out as described (Frommer et al., 1992). The promoter
and first exon of GATA-3 were amplified using primers (forward, GGAATCA
GTGTGCAGTGTGG, reverse, TTAGGAGCTTTGGCTTGCTC; forward, TGCA
GTTTCCTTGTGCTGAG, reverse, CACCTGCAAGGGAGAGAAAG) and then
sequenced for analysis.
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Primary tumors from 3- to 6-month-old MMTV-PyMT mice (FVB/n and C57BL/
6 strains) and primary mammary glands from 3- to 10-month-old wild-type
FVB/n and C57BL/6 mice were harvested, and epithelial cell suspensions
were prepared as previously described (Welm et al., 2005), except that orga-
noids were trypsinized and the resulting suspensions were filtered through
a 70 mM filter. Single cells were labeled with CD24-PE (BD Biosciences),
CD61-biotin (BD), and CD29-FITC (ABD Serotec) at 1:100 dilution, and strep-
tavidin-APC (BD Biosciences) at 1:100 was used for secondary detection.
FACS analysis and cell sorting were performed using a FACSCalibur or
FACSAria and the FlowJo software package.
Cell Culture and Migration Studies
Cell invasion assays were performed using the cell invasion assay kit (Chem-
icon International). Primary tumors were harvested, and cell populations were
sorted by FACS as described above. 1.5 3 105 cells in 300 ml of serum-free
media were placed over the inner gel chamber in a 24-well tissue culture plate,
and 500 ml of serum-containing media was placed in the outer chamber. After
72 hr, the membranes containing migratory cells were developed, and the frac-
tion of the membranes containing stained cells was determined using Adobe
Photoshop.
Supplemental Data
The Supplemental Data include four supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/2/
141/DC1/.
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